Thiogenesis Therapeutics Corp. engages in developing novel drug formulations that act as precursors for rare diseases. The company was founded in 2018 and is headquartered in Toronto, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company